Building a neuromuscular franchise with DNTH103 through additional planned Phase 2 trials in Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) DNTH103 is a ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
Target Levels of Active Drug Achieved in Healthy Volunteers with Oral Twice-Daily Dosing; Supportive Impact on Pharmacodynamic Biomarker of Complement Activity ANX1502 Generally Well Tolerated Across ...
Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...
The figure focuses on complement activation by means of the alternative pathway because it is the one responsible for hemolysis in PNH. The lightning bolt symbolizes the spontaneous hydrolytic ...
A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
A study shows elevated CFHR1 promotes immune complex buildup in kidneys, offering insights into disease mechanisms, enabling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results